Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rothenberg

Showing results (101-110 of 162) with videos related to

Pageof 17
Sort By:
Annals of the New York Academy of Sciences|January 31, 2004
Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type IS Mani, S Goel, M Nesterova, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
New anticancer agentsG R Weiss, H A Burris, J R Eckardt, et al.
Investigational New Drugs|May 9, 2008
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancerDaniel G Stover, A Craig Lockhart, Jordan D Berlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 14, 2008
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority studyM L Rothenberg, J V Cox, C Butts, et al.
The American Journal on Addictions|April 6, 2006
Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trialMaria A Sullivan, Jami L Rothenberg, Suzanne K Vosburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomasLia Gore, Mace L Rothenberg, Cindy L O'Bryant, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 26, 2018
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) InhibitionDebapriya Basu, Lesley-Ann Huggins, Diego Scerbo, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2006
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumorsA C Lockhart, R Bukowski, M L Rothenberg, et al.
Cancer Medicine|January 24, 2013
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studiesKenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.
Pageof 17

Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
Annals of the New York Academy of Sciences|January 31, 2004
Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type IS Mani, S Goel, M Nesterova, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
New anticancer agentsG R Weiss, H A Burris, J R Eckardt, et al.
Investigational New Drugs|May 9, 2008
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancerDaniel G Stover, A Craig Lockhart, Jordan D Berlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 14, 2008
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority studyM L Rothenberg, J V Cox, C Butts, et al.
The American Journal on Addictions|April 6, 2006
Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trialMaria A Sullivan, Jami L Rothenberg, Suzanne K Vosburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomasLia Gore, Mace L Rothenberg, Cindy L O'Bryant, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 26, 2018
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) InhibitionDebapriya Basu, Lesley-Ann Huggins, Diego Scerbo, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2006
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumorsA C Lockhart, R Bukowski, M L Rothenberg, et al.
Cancer Medicine|January 24, 2013
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studiesKenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.
Pageof 17